Bevacizumab, a humanized monoclonal anti-VEGF antibody (3), conferred progression-free survival (PFS) benefit versus historic controls (4), but clinical trials have failed to demonstrate OS benefit for newly diagnosed (5, 6) or recurrent (7) glioblastoma. This evidence concerns the gene VEGFA and glioblastoma.